Prostate stereotactic ablative body radiotherapy using a standard linear accelerator:toxicity, biochemical, and pathological outcomes

Autoria(s): Loblaw, Andrew; Cheung, Patrick; D'Alimonte, Laura; Deabreu, Andrea; Mamedov, Alexandre; Zhang, Liying; Tang, Colin; Quon, Harvey; Jain, Suneil; Pang, Geordi; Nam, Robert
Data(s)

01/05/2013
Resumo

Biological dose escalation through stereotactic ablative radiotherapy (SABR) holds promise of improved patient convenience, system capacity and tumor control with decreased cost and side effects. The objectives are to report the toxicities, biochemical and pathologic outcomes of this prospective study.
Identificador

http://pure.qub.ac.uk/portal/en/publications/prostate-stereotactic-ablative-body-radiotherapy-using-a-standard-linear-accelerator(ea9cd197-7b1a-4f2b-a8f0-fa78fd3c2136).html

http://dx.doi.org/10.1016/j.radonc.2013.03.022
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Loblaw , A , Cheung , P , D'Alimonte , L , Deabreu , A , Mamedov , A , Zhang , L , Tang , C , Quon , H , Jain , S , Pang , G & Nam , R 2013 , ' Prostate stereotactic ablative body radiotherapy using a standard linear accelerator : toxicity, biochemical, and pathological outcomes ' Radiotherapy and Oncology , vol 107 , no. 2 , pp. 153-8 . DOI: 10.1016/j.radonc.2013.03.022
Tipo

article
Acesso ao item digital